CA2657270A1 - New paediatric indications for direct thrombin inhibitors - Google Patents

New paediatric indications for direct thrombin inhibitors Download PDF

Info

Publication number
CA2657270A1
CA2657270A1 CA002657270A CA2657270A CA2657270A1 CA 2657270 A1 CA2657270 A1 CA 2657270A1 CA 002657270 A CA002657270 A CA 002657270A CA 2657270 A CA2657270 A CA 2657270A CA 2657270 A1 CA2657270 A1 CA 2657270A1
Authority
CA
Canada
Prior art keywords
children
disease
compound
dabigatran
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002657270A
Other languages
English (en)
French (fr)
Inventor
Andreas Clemens
Lisa Cronin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38440248&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2657270(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2657270A1 publication Critical patent/CA2657270A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002657270A 2006-07-17 2007-07-13 New paediatric indications for direct thrombin inhibitors Abandoned CA2657270A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP06117347.2 2006-07-17
EP06117347 2006-07-17
EP07102514 2007-02-15
EP07102514.2 2007-02-15
PCT/EP2007/057258 WO2008009640A1 (en) 2006-07-17 2007-07-13 New paediatric indications for direct thrombin inhibitors

Publications (1)

Publication Number Publication Date
CA2657270A1 true CA2657270A1 (en) 2008-01-24

Family

ID=38440248

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002657270A Abandoned CA2657270A1 (en) 2006-07-17 2007-07-13 New paediatric indications for direct thrombin inhibitors

Country Status (8)

Country Link
US (2) US20080015176A1 (enExample)
EP (1) EP2043691A1 (enExample)
JP (1) JP2009543844A (enExample)
AR (1) AR062058A1 (enExample)
CA (1) CA2657270A1 (enExample)
CL (1) CL2007002067A1 (enExample)
TW (1) TW200817000A (enExample)
WO (1) WO2008009640A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100129281A (ko) * 2008-03-28 2010-12-08 베링거 인겔하임 인터내셔날 게엠베하 경구 투여되는 다비가트란 제형의 제조 방법
DE102008025261B4 (de) 2008-05-27 2010-03-18 Rev Renewable Energy Ventures, Inc. Halogeniertes Polysilan und plasmachemisches Verfahren zu dessen Herstellung
US20110123635A1 (en) 2008-07-14 2011-05-26 Boehringer Ingelheim International Gmbh Method for manufacturing medicinal compounds containing dabigatran
EA201100358A1 (ru) * 2008-08-19 2011-10-31 Бёрингер Ингельхайм Интернациональ Гмбх Дабигатран для чрескожной хирургической катетеризации сердца
WO2010020601A1 (en) * 2008-08-19 2010-02-25 Boehringer Ingelheim International Gmbh Dabigatran in tumour therapy
CN102209544A (zh) 2008-11-11 2011-10-05 贝林格尔.英格海姆国际有限公司 使用达比加群酯或其盐治疗或预防血栓形成且与常规的华法林疗法相比具有改良安全性的方法
JP5850046B2 (ja) * 2011-03-25 2016-02-03 日本電気株式会社 通信装置、通信システム及び通信方法
WO2014001220A1 (en) 2012-06-25 2014-01-03 Boehringer Ingelheim International Gmbh Method for prevention of stroke
CN105440017B (zh) * 2014-08-19 2018-03-02 天津药物研究院 达比加群酯香草酸盐及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) * 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
SI1870100T1 (sl) * 2002-03-07 2012-05-31 Boehringer Ingelheim Int Metansulfonat etil estra heksiloksikarbonilamino imino metil fenilamino metil metil H benzimidazol karbonil piridin il amino propionske kisline
KR20060007034A (ko) * 2003-04-24 2006-01-23 베링거 인겔하임 인터내셔날 게엠베하 혈전색전증 질환 및 트롬빈의 과형성 및/또는 트롬빈수용체의 상승된 발현에 의해 유발된 질환 및 장애를치료하고 예방하기 위한, 디피리다몰 또는 모피다몰의 용도
WO2004112645A2 (en) * 2003-06-17 2004-12-29 Brown Ward M Subcutaneous lead system
US8569277B2 (en) * 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition

Also Published As

Publication number Publication date
CL2007002067A1 (es) 2008-01-25
US20080015176A1 (en) 2008-01-17
AR062058A1 (es) 2008-10-15
TW200817000A (en) 2008-04-16
WO2008009640A1 (en) 2008-01-24
EP2043691A1 (en) 2009-04-08
JP2009543844A (ja) 2009-12-10
US20110015129A1 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
CA2657266A1 (en) New indications for direct thrombin inhibitors in the cardiovascular field
US20110015129A1 (en) New paediatric indications for direct thrombin inhibitors
CA2657269A1 (en) New indications for direct thrombin inhibitors
HUE034869T2 (en) Combination therapy with substituted oxazolidinones
JP2004504389A (ja) シアノメチル置換化チアゾリウム及びイミダゾリウム、並びにタンパク質老化と関連する疾患の治療
JP2008534552A5 (enExample)
EP1845961B1 (en) Treatment of thromboembolic disorders with rivaroxaban
JP2009543844A5 (enExample)
AU2021256963B2 (en) Inhibitors of TRPC6 for treating respiratory conditions
CN101489549A (zh) 直接凝血酶抑制剂在心血管领域的新的适应症
CA3089970A1 (en) Therapeutic compounds and compositions
JP2004244409A (ja) 糖尿病の発症予防薬
JP6336484B2 (ja) 遅延ナトリウム電流遮断薬および洞房結節ｉｆ電流阻害薬の組合せ、ならびに該組合せを含む医薬組成物
HK1133402A (en) New indications for direct thrombin inhibitors in the cardiovascular field
KR20100137448A (ko) 혈관성 질병의 예방제 및/또는 치료제
KR20100015675A (ko) 폐 고혈압의 치료 및 예방을 위한 옥사졸리디논
JPH08165239A (ja) 抗動脈硬化剤
HK1144255A (en) Oxazolidinone for the treatment and prophylaxis of pulmonary hypertension
JP2014070051A (ja) ニペコチン酸誘導体及びその医薬用途
KR20090090748A (ko) 조합 성분을 함유한 혈관질환 예방치료제
JP2007186469A (ja) ピペリジン誘導体を有効成分とする抗血小板剤

Legal Events

Date Code Title Description
FZDE Discontinued